1、上尿路移行细胞癌预后因素研究进展2、甘肃省临洮县新添中心卫生院基本药物政策实施绩效调查
|
摘要
背景上尿路移行细胞癌(UTUC)起源于尿路上皮,位于肾盏肾盂或输尿管,发病率较低,UTUC的生物学特性和预后存在异质性。肾输尿管切除及膀胱袖状切除认为是治疗UTUC勺金标准。而美国国家癌症网指南认为UTUC高危患者需考虑行局部淋巴结清扫及新辅助化疗,而低危患者可行保守治疗(如内镜下肿瘤切除或部分切除)且获益更大。风险分级对指导治疗、随访、辅助化疗等起着不可替代的作用,因此研究预后因素进而对UTUC患者进行风险分级显得尤为重要。
目的归纳总结可能影响UTUC勺预后因素,包括临床因素、手术因素、病理因素及肿瘤标记物。
方法由第一作者检索2000年1月-2012年12月Pub Med数据库和中国知网数据库收录的与上尿路移行细胞癌预后因素研究相关的文献。英文检索词为"upper tract urothelial carcinoma或upper urinary tract carcinoma, prognosis或prognostic factor,markers, survival";中文检索词为“上尿路移行细胞癌或上尿路尿路上皮细胞癌,预后因素,预后,分子标记物,生存率”。根据纳入标准保留61篇文献进行论述。
结果UTUC的预后因素可归纳为四类,分别为临床因素、手术因素、病理因素及肿瘤标记物。由于发病率较低,预后因素从前瞻性的随机试验获得的证据很少,而大部分信息来源于单中心或多中心的回顾性研究。肿瘤分期、分级是影响UTUC预后的独立因素基本得到认可,而肿瘤位置和肿瘤坏死能否作为影响预后的独立因素仍然存在争议。已经研究发现了很多肿瘤标志物与肿瘤侵袭性、复发、肿瘤生存率密切相关,但应用临床还需进一步的研究。UTUC患者预后风险的分级需综合考虑各个预后因素,而可用于指导临床评估的预后模型仍缺乏。
结论在过去的十余年里,一些影响UTUC的预后因素得到进一步的认证,为临床医师治疗策略的制定提供了参考。UTUC预后因素的研究绝大部分都是回顾性研究,许多结论尚需前瞻性多中心研究进行明确,以进一步促进预后因素对临床治疗的指导作用。
目的国家基本药物制度是一项惠民政策,本课题是“十一五”国家科技支撑计划重点项目“基本型乡镇卫生院技术集成综合示范”研究的子课题,要求探索欠发达地区乡镇卫生院的基本药物应用情况,并选择了一家能代表我国经济欠发达地区乡镇卫生院(甘肃省临洮县新添中心卫生院)为试点。通过调查新添中心卫生院基本药物(EML)政策一年来的实施绩效,了解该院EML实施存在的问题,为欠发达地区乡镇卫生院基本药物配送、存储、补偿机制等研究提供依据。
方法采用问卷调查和专题访谈相结合的法,调查该院EML配备和使用情况、EML政策实施前后诊疗业务和收支变化等情况。
结果①新添中心卫生院EML配备率呈递增趋势,由实施前的62.2%增至87.3%。EML药物所占药品销售额的比例也由39.3%增至90.6%。但存在配送品种不全、品种落后的问题。
②EML实施后,l卫生院门诊人次数、出院人次数均有所上升,次均门诊费用、次均住院费用均有不同程度的下降。
③EML实施后,医院总收入略有增加,但限于财政补助额度,卫生院经营尚处于亏损。
④医药比持续降低,卫生院药品费用与检查费用比例呈上升趋势。尤其2010-2011年检查费用所占比例较2009年增长30%左右,且EML实施后检查费用并未降低。
结论EML的实施并未根本改善“以药养医”的现状。药物零差价销售,卫生院补偿机制尚未健全,卫生院财务尚处于亏损。建议开展药物的循证遴选,并开展针对欠发达地区政府补偿机制的研究。
Background Upper tract urothelial carcinoma (UTUC) is derived from the urothelium and located in the upper urinary tract (pyelocaliceal cavities, ureter), is a rare diseases and heterogeneous in biology and prognosis. Radical nephroureterectomy (RNU) with bladder-cuff removal is considered the gold standard treatment of UTUC. According to the American National Comprehensive Cancer Network guidelines, regional lymphadenectomy and neoadjuvant chemotherapy should also be considered in selected patients with high-risk disease. Conversely, some patients with low-risk disease may benefit from a more conservative approach (eg, endoscopic ablation, segmental resection). Risk classification plays an irreplaceable role in guiding treatment, follow-up, and adjuvant chemotherapy for UTUC.So it is particularly important to study prognostic factors and to predict the individual patient's risk level.
Objective Provide an overview of the currently available prognostic factors for UTUC, focusing on clinical, surgical and pathological factors, as well as on tumor markers.
Methods A search of PubMed and CNKI databases (2000/1-2012/12) was performed by the first author for the literature of the upper tract urothelial carcinoma and prognostic factor. The keywords were "upper tract urothelial carcinoma or upper urinary tract carcinoma, prognosis or prognostic factor, markers, survival" in English and Chinese, respectively. Unrelated articles or repetitive articles were excluded, and finally61articles were included in result analysis.
Results Prognostic factors can be divided into four categories:clinical factors, surgical factors, pathologic factors, and tumor markers. Because of the rarity of the disease, only a small amount information is from prospective randomized trials. Conversely information on various prognostic factors is from several single-institutional and multi-institutional retrospective studies. Several tumor markers were found to be associated with tumor aggressiveness, tumor recurrence and patient survival, but further studies evaluating their prognostic role in clinical practice are still needed. Risk classification should take all prognostic factors into consideration, and few prognostic models have been developed to provide clinical accurate risk estimates.
Conclusion tn the past ten years, several prognostic factors have been identified to help clinicians dealing with patients with UTUC in the decision-making process. The vast majority studies of prognostic factors were retrospective studies, multi-institutional prospective studies are needed to confirm their prognostic role and to promote the use of these prognostic factors in clinical practice.
Objective National Essential Medicines policy is good for our country and people. This study is from National Key Technology R&D Program in the11th Five year Plan of china-Integration and Demonstration of basic township health center. To investigate the performance of essential medicine policy in township hospital of less developed areas is one topic of this project. And we chose Xintian Township Health Center (XTHC) as the pilot, which is typical for the township hospitals in less developed areas. To investigate the performance of Essential Medicine List (EML) policy over the past one year in Xintian Township Health Center(XTHC),so as to provide references for the delivery,storage and compensation mechanism of essential medicine for township hospitals.
Methods Focus interview combined with a questionnaire was carried out to investigate the supply and usage of EML, the situation of both diagnosis-treatment services and the income-expenditure changes before and after EML policy.
Results a) It showed that there was an increasing trend with the preparation rate of EML from62.2%before implementation to87.3%after, and the proportion of EML income to total medicine expenses increased from39.3%to90.6%in XTHC. But problems still existed such as incomplete and old variety of medicine;
b) The numbers of outpatient-time and inpatient-time kept growing, while medical cost for both average clinic cost and average hospitalization cost decreased to different extent;
c) Although the gross income increased slightly, this center was still running in the red with the limited amount of financial assistance;
d) The proportion of medical care and drug kept decreasing while the proportion of drug cost and examination cost kept increasing. Compared with the situation in2009, the proportion of examination cost from2010to2011had increased by30%, and it still remained at the previous level after EML implementation.
Conclusion The implementation of EML does not completely change the predicament of "Make compensation for doctors by selling drugs" in township health center. Owing to the sale policy of zero price difference and the poor performance of compensation for township health centers. XTHC is still running under deficit. Evidence-based medicine selection and research on compensation mechanism for underdeveloped areas are urgent needed.
目的归纳总结可能影响UTUC勺预后因素,包括临床因素、手术因素、病理因素及肿瘤标记物。
方法由第一作者检索2000年1月-2012年12月Pub Med数据库和中国知网数据库收录的与上尿路移行细胞癌预后因素研究相关的文献。英文检索词为"upper tract urothelial carcinoma或upper urinary tract carcinoma, prognosis或prognostic factor,markers, survival";中文检索词为“上尿路移行细胞癌或上尿路尿路上皮细胞癌,预后因素,预后,分子标记物,生存率”。根据纳入标准保留61篇文献进行论述。
结果UTUC的预后因素可归纳为四类,分别为临床因素、手术因素、病理因素及肿瘤标记物。由于发病率较低,预后因素从前瞻性的随机试验获得的证据很少,而大部分信息来源于单中心或多中心的回顾性研究。肿瘤分期、分级是影响UTUC预后的独立因素基本得到认可,而肿瘤位置和肿瘤坏死能否作为影响预后的独立因素仍然存在争议。已经研究发现了很多肿瘤标志物与肿瘤侵袭性、复发、肿瘤生存率密切相关,但应用临床还需进一步的研究。UTUC患者预后风险的分级需综合考虑各个预后因素,而可用于指导临床评估的预后模型仍缺乏。
结论在过去的十余年里,一些影响UTUC的预后因素得到进一步的认证,为临床医师治疗策略的制定提供了参考。UTUC预后因素的研究绝大部分都是回顾性研究,许多结论尚需前瞻性多中心研究进行明确,以进一步促进预后因素对临床治疗的指导作用。
目的国家基本药物制度是一项惠民政策,本课题是“十一五”国家科技支撑计划重点项目“基本型乡镇卫生院技术集成综合示范”研究的子课题,要求探索欠发达地区乡镇卫生院的基本药物应用情况,并选择了一家能代表我国经济欠发达地区乡镇卫生院(甘肃省临洮县新添中心卫生院)为试点。通过调查新添中心卫生院基本药物(EML)政策一年来的实施绩效,了解该院EML实施存在的问题,为欠发达地区乡镇卫生院基本药物配送、存储、补偿机制等研究提供依据。
方法采用问卷调查和专题访谈相结合的法,调查该院EML配备和使用情况、EML政策实施前后诊疗业务和收支变化等情况。
结果①新添中心卫生院EML配备率呈递增趋势,由实施前的62.2%增至87.3%。EML药物所占药品销售额的比例也由39.3%增至90.6%。但存在配送品种不全、品种落后的问题。
②EML实施后,l卫生院门诊人次数、出院人次数均有所上升,次均门诊费用、次均住院费用均有不同程度的下降。
③EML实施后,医院总收入略有增加,但限于财政补助额度,卫生院经营尚处于亏损。
④医药比持续降低,卫生院药品费用与检查费用比例呈上升趋势。尤其2010-2011年检查费用所占比例较2009年增长30%左右,且EML实施后检查费用并未降低。
结论EML的实施并未根本改善“以药养医”的现状。药物零差价销售,卫生院补偿机制尚未健全,卫生院财务尚处于亏损。建议开展药物的循证遴选,并开展针对欠发达地区政府补偿机制的研究。
Background Upper tract urothelial carcinoma (UTUC) is derived from the urothelium and located in the upper urinary tract (pyelocaliceal cavities, ureter), is a rare diseases and heterogeneous in biology and prognosis. Radical nephroureterectomy (RNU) with bladder-cuff removal is considered the gold standard treatment of UTUC. According to the American National Comprehensive Cancer Network guidelines, regional lymphadenectomy and neoadjuvant chemotherapy should also be considered in selected patients with high-risk disease. Conversely, some patients with low-risk disease may benefit from a more conservative approach (eg, endoscopic ablation, segmental resection). Risk classification plays an irreplaceable role in guiding treatment, follow-up, and adjuvant chemotherapy for UTUC.So it is particularly important to study prognostic factors and to predict the individual patient's risk level.
Objective Provide an overview of the currently available prognostic factors for UTUC, focusing on clinical, surgical and pathological factors, as well as on tumor markers.
Methods A search of PubMed and CNKI databases (2000/1-2012/12) was performed by the first author for the literature of the upper tract urothelial carcinoma and prognostic factor. The keywords were "upper tract urothelial carcinoma or upper urinary tract carcinoma, prognosis or prognostic factor, markers, survival" in English and Chinese, respectively. Unrelated articles or repetitive articles were excluded, and finally61articles were included in result analysis.
Results Prognostic factors can be divided into four categories:clinical factors, surgical factors, pathologic factors, and tumor markers. Because of the rarity of the disease, only a small amount information is from prospective randomized trials. Conversely information on various prognostic factors is from several single-institutional and multi-institutional retrospective studies. Several tumor markers were found to be associated with tumor aggressiveness, tumor recurrence and patient survival, but further studies evaluating their prognostic role in clinical practice are still needed. Risk classification should take all prognostic factors into consideration, and few prognostic models have been developed to provide clinical accurate risk estimates.
Conclusion tn the past ten years, several prognostic factors have been identified to help clinicians dealing with patients with UTUC in the decision-making process. The vast majority studies of prognostic factors were retrospective studies, multi-institutional prospective studies are needed to confirm their prognostic role and to promote the use of these prognostic factors in clinical practice.
Objective National Essential Medicines policy is good for our country and people. This study is from National Key Technology R&D Program in the11th Five year Plan of china-Integration and Demonstration of basic township health center. To investigate the performance of essential medicine policy in township hospital of less developed areas is one topic of this project. And we chose Xintian Township Health Center (XTHC) as the pilot, which is typical for the township hospitals in less developed areas. To investigate the performance of Essential Medicine List (EML) policy over the past one year in Xintian Township Health Center(XTHC),so as to provide references for the delivery,storage and compensation mechanism of essential medicine for township hospitals.
Methods Focus interview combined with a questionnaire was carried out to investigate the supply and usage of EML, the situation of both diagnosis-treatment services and the income-expenditure changes before and after EML policy.
Results a) It showed that there was an increasing trend with the preparation rate of EML from62.2%before implementation to87.3%after, and the proportion of EML income to total medicine expenses increased from39.3%to90.6%in XTHC. But problems still existed such as incomplete and old variety of medicine;
b) The numbers of outpatient-time and inpatient-time kept growing, while medical cost for both average clinic cost and average hospitalization cost decreased to different extent;
c) Although the gross income increased slightly, this center was still running in the red with the limited amount of financial assistance;
d) The proportion of medical care and drug kept decreasing while the proportion of drug cost and examination cost kept increasing. Compared with the situation in2009, the proportion of examination cost from2010to2011had increased by30%, and it still remained at the previous level after EML implementation.
Conclusion The implementation of EML does not completely change the predicament of "Make compensation for doctors by selling drugs" in township health center. Owing to the sale policy of zero price difference and the poor performance of compensation for township health centers. XTHC is still running under deficit. Evidence-based medicine selection and research on compensation mechanism for underdeveloped areas are urgent needed.
引文
[1]Lughezzani G, Sun M, Perrotte P, et al. Gender-related differences in patients with stage I to III upper tract urothelial carcinoma:results from the Surveillance, Epidemiology, and End Results database[J]. Urology,2010,75(2):321-327.
[2]Fernandez MI, Shariat SF, Margulis V, et al. Evidence-based sex-related outcomes after radical nephroureterectomy for upper tract urothelial carcinoma:results of large multicenter study[J]. Urology,2009,73(1):142-146.
[3]Cha EK, Shariat SF, Kormaksson M, et al. Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma[J]. Eur Urol,2012,61(4): 818-825.
[4]Chromecki TF, Ehdaie B, Novara G, et al. Chronological age is not an independent predictor of clinical outcomes after radical nephroureterectomy[J]. World J Urol,2011. 29(4):473-480.
[5]Shariat SF, Godoy G, Lotan Y, et al. Advanced patient age is associated with inferior cancer-specific survival after radical nephroureterectomy[J]. BJU Int,2010,105(12): 1672-1677.
[6]Raman JD, Messer J, Sielatycki JA, et al. Incidence and survival of patients with carcinoma of the ureter and renal pelvis in the USA,1973-2005[J]. BJU Int,2011,107(7): 1059-1064.
[7]Matsumoto K, Novara G, Gupta A. et al. Racial differences in the outcome of patients with urothelial carcinoma of the upper urinary tract:an international study[J]. BJU Int, 2011,108(8Pt2):E304-309.
[8]Martinez-Salamanca JI, Shariat SF, Rodriguez JC. et al. Prognostic role of ECOG performance status in patients with urothelial carcinoma of the upper urinary tract:an international study[J]. BJU Int,2012,109(8):1155-1161.
[9]Ehdaie B, Chromecki TF, Lee RK, et al. Obesity adversely impacts disease specific outcomes in patients with uppertract urothelial carcinoma[J]. J Urol,2011,186(1):66-72.
[10]Ehdaie B, Furberg H, Zabor EC, et al. Impact of smoking status at diagnosis on disease recurrence and death in upper tract urothelial carcinoma[J]. BJU Int.2012. doi: 10.1111/j.1464-410X.2012.11260.x
[11]Rink M. Xylinas E, Margulis V, et al. Impact of Smoking on Oncologic Outcomes of Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy[J]. Eur Urol,2012. doi:10.1016/j.eururo.2012.06.029.
[12]Raman JD, Ng CK, Scherr DS, et al. Impact of tumor location on prognosis for patients with upper tract urothelial carcinoma managed by radical nephroureterectomy [J]. Eur Urol,2010,57(6):1072-1079.
[13]Yafi FA, Novara G, Shariat SF, et al. Impact of tumour location versus multifocality in patients with upper tract urothelial carcinoma treated with nephroureterectomy and bladder cuff excision:a homogeneous series without perioperative chemotherapy[J]. BJU Int,2012,110(2 Pt 2):E7-13.
[14]Rink M, Ehdaie B, Cha EK, et al. Stage-Specific Impact of Tumor Location on Oncologic Outcomes in Patients With Upper and Lower Tract Urothelial Carcinoma Following Radical Surgery[J]. Eur Urol,2012,62(4):677-684.
[15]Cosentino M, Palou J, Gaya JM, et al. Upper urinary tract urothelial cell carcinoma: location as a predictive factor for concomitant bladder carcinoma[J]. World J Urol,2012. doi:10.1007/s00345-012-0877-2
[16]Zigeuner RE, Hutterer G, Chromecki T, et al. Bladder tumour development after urothelial carcinoma of the upper urinary tract is related to primary tumour location[J]. BJU Int, 2006,98(6):1181-1186.
[17]Raman JD, Shariat SF, Karakiewicz PI, et al. Does preoperative symptom classification impact prognosis in patients with clinically localized upper-tract urothelial carcinoma managed by radical nephroureterectomy?[J]. Urol Oncol,2011,29(6):716-723.
[18]Ito Y, Kikuchi E, Tanaka N, et al. Preoperative hydronephrosis grade independently predicts worse pathological outcomes in patients undergoing nephroureterectomy for upper tract urothelial carcinoma[J]. J Urol,2011,185(5):1621-1626.
[19]Ng CK, Shariat SF, Lucas SM, et al. Does the presence of hydronephrosis on preoperative axial CT imaging predict worse outcomes for patients undergoing nephroureterectomy for upper-tract urothelial carcinoma?[J]. Urol Oncol,2011,29(1):27-32.
[20]Messer JC, Terrell JD. Herman MP, et al. Multi-institutional validation of the ability of preoperative hydronephrosis to predict advanced pathologic tumor stage in upper-tract urothelial carcinoma[J]. Urol Oncol,2011. doi:10.1016/j.urolonc.2011.07.011
[21]Mullerad M, Russo P, Golijanin D, et al. Bladder cancer as a prognostic factor for upper tract transitional cell carcinoma[J]. J Urol,2004,172(6 Pt 1):2177-2181.
[22]Novara G, De Marco V. Gottardo F, et al. Independent predictors of cancer-specific survival in transitional cell carcinoma of the upper urinary tract:multi-institutional dataset from 3 European centers[J]. Cancer,2007,110(8):1715-1722.
[23]Boorjian S, Ng C, Munver R, et al. Impact of delay to nephroureterectomy for patients undergoing ureteroscopic biopsy and laser tumor ablation of upper tract transitional cell carcinoma[J]. Urology,2005,66(2):283-287.
[24]Waldert M. Karakiewicz PI, Raman JD, et al. A delay in radical nephroureterectomy can lead to upstaging[J]. BJU Int,2010,105(6):812-817.
[25]Gadzinski AJ, Roberts WW, Faerber GJ, et al. Long-term outcomes of immediate versus delayed nephroureterectomy for upper tract urothelial carcinoma[J]. J Endourol,2012, 26(5):566-573.
[26]Sundi D, Svatek RS, Margulis V, et al. Upper tract urothelial carcinoma:impact of time to surgery[J], Urol Oncol,2012,30(3):266-272.
[27]Stewart GD, Humphries K.J, Cutress ML, et al. Long-term comparative outcomes of open versus laparoscopic nephroureterectomy for upper urinary tract urothelial-cell carcinoma after a median follow-up of 13 years*[J]. J Endourol,2011,25(8):1329-1335.
[28]Ni S, Tao W. Chen Q, et al. Laparoscopic versus open nephroureterectomy for the treatment of upper urinary tract urothelial carcinoma:a systematic review and cumulative analysis of comparative studies[J]. EurUrol,2012,61(6):1142-1153.
[29]Xylinas E, Rink M, Cha EK, et al. Impact of Distal Ureter Management on Oncologic Outcomes Following Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma[J]. EurUrol,2012. http://dx.doi.org/10.1016/j.eururo.2012.04.052
[30]龚宇,杜传军,陈继民等.经尿道钬激光、电切及开放手术处理膀胱袖套-输尿管下段的对照研究[J].中华泌尿外科杂志,2012,33(5)：347-350.
[31]Miyake H, Hara 1, Gohji K, et al. The significance of lymphadenectomy in transitional cell carcinoma of the upper urinary tract[J]. Br J Urol,1998,82(4):494-498.
[32]Brausi MA, Gavioli M, De Luca G, et al. Retroperitoneal lymph node dissection (RPLD) in conjunction with nephroureterectomy in the treatment of infiltrative transitional cell carcinoma (TCC) of the upper urinary tract:impact on survival[J]. Eur Urol,2007,52(5): 1414-1418.
[33]Roscigno M, Cozzarini C, Bertini R, et al. Prognostic value of lymph node dissection in patients with muscle-invasive transitional cell carcinoma of the upper urinary tract[J]. Eur Urol,2008,53(4):794-802.
[34]Roscigno M, Shariat SF, Margulis V, et al. Impact of lymph node dissection on cancer specific survival in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy[J]. J Urol,2009,181(6):2482-2489.
[35]Rondo T, Hashimoto Y, Kobayashi H, et al. Template-based lymphadenectomy in urothelial carcinoma of the upper urinary tract:impact on patient survival[J]. Int J Urol, 2010,17(10):848-854.
[36]Lughezzani G, Jeldres C, Isbarn H, et al. A critical appraisal of the value of lymph node dissection at nephroureterectomy for upper tract urothelial carcinoma[J]. Urology,2010, 75(1):118-124.
[37]Mason RJ, Kassouf W, Bell DG, et al. The contemporary role of lymph node dissection during nephroureterectomy in the management of upper urinary tract urothelial carcinoma: the Canadian experience[J]. Urology,2012,79(4):840-845.
[38]陈明,徐丹枫,崔心刚等.上尿路移行细胞癌预后的多因素分析[J].第二军医大学学报,2008,(10)：1217-1220.
[39]Margulis V, Shariat SF, Matin SF, et al. Outcomes of radical nephroureterectomy:a series from the Upper Tract Urothelial Carcinoma Collaboration[J]. Cancer,2009,115(6): 1224-1233.
[40]Langner C, Hutterer G, Chromecki T, et al. pT classification, grade, and vascular invasion as prognostic indicators in urothelial carcinoma of the upper urinary tract[J]. Mod Pathol, 2006,19(2):272-279.
[41]Li WM, Li CC, Ke HL, et al. The prognostic predictors of primary ureteral transitional cell carcinoma after radical nephroureterectomy[J]. J Urol.2009,182(2):451-458; discussion 458.
[42]Li CC, Chang TH, Wu WJ, et al. Significant predictive factors for prognosis of primary upper urinary tract cancer after radical nephroureterectomy in Taiwanese patients[J]. Eur Urol,2008,54(5):1127-1134.
[43]Simone G, Papalia R, Loreto A, et al. Independent prognostic value of tumour diameter and tumour necrosis in upper urinary tract urothelial carcinoma[J]. BJU Int,2009,103(8): 1052-1057.
[44]Pieras E, Frontera G, Ruiz X, et al. Concomitant carcinoma in situ and tumour size are prognostic factors for bladder recurrence after nephroureterectomy for upper tract transitional cell carcinoma[J]. BJU Int,2010,106(9):1319-1323.
[45]Langner C, Hutterer G, Chromecki T, et al. Patterns of invasion and histological growth as prognostic indicators in urothelial carcinoma of the upper urinary tract[J]. Virchows Arch, 2006,448(5):604-611.
[46]Remzi M, Haitel A, Margulis V, et al. Tumour architecture is an independent predictor of outcomes after nephroureterectomy:a multi-institutional analysis of 1363 patients[J]. BJU Int,2009,103(3):307-311.
[47]Fritsche HM, Novara G, Burger M, et al. Macroscopic sessile tumor architecture is a pathologic feature of biologically aggressive upper tract urothelial carcinoma[J]. Urol Oncol,2012,30(5):666-672.
[48]Wheat JC, Weizer AZ, Wolf JS, Jr., et al. Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ confined urothelial carcinoma following radical nephroureterectomy[J]. Urol Oncol,2012,30(3):252-258.
[49]Langner C, Hutterer G, Chromecki T, et al. Tumor necrosis as prognostic indicator in transitional cell carcinoma of the upper urinary tract[J]. J Urol,2006,176(3):910-913; discussion 913-914.
[50]Lee SE, Hong SK, Han BK, et al. Prognostic significance of tumor necrosis in primary transitional cell carcinoma of upper urinary tract[J]. Jpn J Clin Oncol,2007,37(1):49-55.
[51]Zigeuner R, Shariat SF, Margulis V, et al. Tumour necrosis is an indicator of aggressive biology in patients with urothelial carcinoma of the upper urinary tract[J]. Eur Urol,2010, 57(4):575-581.
[52]Seitz C, Gupta A. Shariat SF, et al. Association of tumor necrosis with pathological features and clinical outcome in 754 patients undergoing radical nephroureterectomy for upper tract urothelial carcinoma:an international validation study[J]. J Urol,2010,184(5): 1895-1900.
[53]Chromecki TF. Cha EK, Fajkovic H. et al. The impact of tumor multifocality on outcomes in patients treated with radical nephroureterectomy[J]. Eur Urol,2012.61(2):245-253.
[54]Bolenz C, Fernandez MI, Trojan L, et al. Lymphovascular invasion and pathologic tumor stage are significant outcome predictors for patients with upper tract urothelial carcinoma[J]. Urology,2008,72(2):364-369.
[55]Lin WC, Hu FC, Chung SD, et al. The role of lymphovascular invasion in predicting the prognosis of clinically localized upper tract urothelial carcinoma (pT1-3cN0MO)[J]. J Urol,2008,180(3):879-884:discussion 884-875.
[56]Kikuchi E, Margulis V, Karakiewicz PI, et al. Lymphovascular invasion predicts clinical outcomes in patients with node-negative upper tract urothelial carcinoma[J]. J Clin Oncol, 2009,27(4):612-618.
[57]Novara G, Matsumoto K, Kassouf W, et al. Prognostic role of lymphovascular invasion in patients with urothelial carcinoma of the upper urinary tract:an international validation study[J]. Eur Urol,2010,57(6):1064-1071.
[58]Colin P, Ouzzane A, Yates DR, et al. Influence of positive surgical margin status after radical nephroureterectomy on upper urinary tract urothelial carcinoma survival[J]. Ann Surg Oncol,2012,19(11):3613-3620.
[59]吉日嘎拉,王璠,余大海,et a1.凋亡抑制蛋白Livin在上尿路移行细胞癌中的表达及其与预后的关系[J].中国实验诊断学,2012,(10)：1845-1848.
[60]费翔,宋永胜.脂肪酸合成酶在上尿路移行细胞癌组织表达的临床意义及预后相关性分析[J].山西医药杂志,2012,(01)：20-22.
[61]Lughezzani G, Burger M, Margulis V, et al. Prognostic factors in upper urinary tract urothelial carcinomas:a comprehensive review of the current literature[J]. Eur Urol,2012, 62(1):100-114.
[1]Laing R, Waning B, Gray A, Ford N, t Hoen E.25 years of the WHO essential medicines lists:progress and challenges [J]. Lancet 2003;361(9370):1723-9.
[2]The selection and use of essential medicines. Report of the WHO Expert Committee,2002 (including the 12th Model list of essential medicines) [J]. World Health Organ Tech Rep Ser 2003;914:i-vi.1-126.
[3]徐文娟.我国基本药物目录及其实施现况[D].：复旦大学,2012.
[4]关于印发《关于建立国家基本药物制度的实施意见》的通知,卫药政发[2009]78号,2009.
[5]关于印发《国家基本药物目录管理办法(暂行)》的通知.卫药政发[2009]79号,2009.
[6]中华人民共和国卫生部.《国家基本药物目录(基层医疗卫生机构配备使用部分)》(2009版)(卫生部令第69号).2009.
[7]关于在试点地区加快实施国家基本药物制度的通知,甘卫规财发[2010]180号Available from:UR L:http://www.gsws.gov.cn/html/2/5/14828.htm
[8]郑访江.医疗卫生管理.国家基本药物制度[Z].甘肃年鉴：2011.
[9]甘肃省卫生厅,《甘肃省国家基本药物增补目录》(2011年版·基层部分),2011.
[10]蒋虹丽,陈鸣声,陈文,张璐莹,茅雯辉.国家基本药物制度实施的阶段性效果和问题分析[J].中国卫生信息管理杂志,2012,9(1)：40-43.
[11]孙强,左根永,李凯,孟庆跃,何平.实施基本药物制度是否降低了农村居民的医药费用负担：来自安徽三县区的经验[J].中国卫生经济,2012,31(4)：65-67.
[12]沈建通,杨晓妍,李幼平等.甘肃省临洮县新添中心卫生院基本情况现况调查[J].中国循证医学杂志,2011,11(2)：125-130.
[13]李鸿浩,杨晓妍,李幼平,等.甘肃省临洮县新添中心卫生院2008-2010年度住院疾病构成与费用情况调查[J].中国循证医学杂志,2011,11(2)：131-7.
[14]盛来运,严建辉总编.一、主题报告篇,2011年社会事业发展报告[z].中国发展报告：2012,.
[15]关于印发《甘肃省国家基本药物管理办法(试行)》的通知Available from:URL: http://www.gsws.gov.cn/html/2/9/13967.htm.
[16]王莉,周帮旻,宋佳佳等.25国基本药物目录循证评价[J].中国循证医学杂志,2009,9(7)：754-764.
[17]耿劲松,董建成,蒋葵等.我国基层医疗卫生机构增补药物目录的循证分析[J].中国循证医学杂志,2011,11(1)：35-38.
[18]尹爱田,李新泰.山东省基本药物制度对乡镇卫生院门诊服务的影响研究[J].中国卫生经济,2011,30(4)：20-22.
[19]张丽青,黄术生.基本药物制度实施对乡镇卫生院的影响和建议[J].中国卫生事业竹理,2011,28(6)：438-439.
[20]何平,刘博,孙强等.基本药物制度改革前后乡镇卫生院药品价格比较——基于安徽省三县的抽样调查[J].中国卫生政策研究,2011,04(7)：11-16.
[21]于风华,孟庆跃,王健等.基本药物零差率销售对乡镇卫生院经济补偿的影响研究[J].中国卫生经济,2011,30(1)：42-44.
[22]贾金忠,谢一萍,段琳等.基本药物制度实施与乡镇卫生院补偿机制转变[J].中国医院管理,2011,31(10)：37-39.
[23]李新泰,工文华,尹爱田等.山东省基本药物制度对乡镇卫生院合理用药的影响[J].中国卫生经济,2011,30(4)：22-23.
[24]孟锐,邹萍,张师瑞等.完善基本药物制度促进临床合理用药[J].中国药业,2010,19(4)：1-2.
[25]王晓蓉,皮墨.基层医疗卫生机构实施基本药物制度的补偿机制探讨[J].中国卫生经济,2011,30(9)：27-28.
[1]沈建通,杨晓妍,李幼平等.甘肃省临洮县新添中心卫生院基本情况现况调查[J].中国循证医学杂志,2011,11(2)：125-130.
[2]中华人民共和国住房和城乡建设部,中华人民共和国国家发展和改革委员会,乡镇卫生院建设标准[S],北京：中国计划出版社,2009.
[3]汤光,李大魁,袁锁中主编,《优良药房工作规范》(2005年版)(一)[J].中国医院药房药学杂志,2006.26(5)：503507.
[4]刘彦,基层药房的建设和管理[J].管理观察,2010,32：208-209
[5]卫生部、国家中医药管理局和总后勤部卫生部,医疗机构药事管理规定[S],卫医政发[2011],11号
[6]国务院办公厅.建立和规范政府办基层医疗卫生机构基本药物采购机制的指导意见[S],国办发[2010]56号
[7]中华人民共和国国务院令第360号.中华人民共和国药品管理法实施条例[S].2002年9月15口.
[8]主席令第45号.中华人民共和国药品管理法[S].2001年12月1日.
[9]中华人民共和国卫生部令81号、中华人民共和国卫生部,《药品不良反应报告和监测管理办法》[S].
[2]Fernandez MI, Shariat SF, Margulis V, et al. Evidence-based sex-related outcomes after radical nephroureterectomy for upper tract urothelial carcinoma:results of large multicenter study[J]. Urology,2009,73(1):142-146.
[3]Cha EK, Shariat SF, Kormaksson M, et al. Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma[J]. Eur Urol,2012,61(4): 818-825.
[4]Chromecki TF, Ehdaie B, Novara G, et al. Chronological age is not an independent predictor of clinical outcomes after radical nephroureterectomy[J]. World J Urol,2011. 29(4):473-480.
[5]Shariat SF, Godoy G, Lotan Y, et al. Advanced patient age is associated with inferior cancer-specific survival after radical nephroureterectomy[J]. BJU Int,2010,105(12): 1672-1677.
[6]Raman JD, Messer J, Sielatycki JA, et al. Incidence and survival of patients with carcinoma of the ureter and renal pelvis in the USA,1973-2005[J]. BJU Int,2011,107(7): 1059-1064.
[7]Matsumoto K, Novara G, Gupta A. et al. Racial differences in the outcome of patients with urothelial carcinoma of the upper urinary tract:an international study[J]. BJU Int, 2011,108(8Pt2):E304-309.
[8]Martinez-Salamanca JI, Shariat SF, Rodriguez JC. et al. Prognostic role of ECOG performance status in patients with urothelial carcinoma of the upper urinary tract:an international study[J]. BJU Int,2012,109(8):1155-1161.
[9]Ehdaie B, Chromecki TF, Lee RK, et al. Obesity adversely impacts disease specific outcomes in patients with uppertract urothelial carcinoma[J]. J Urol,2011,186(1):66-72.
[10]Ehdaie B, Furberg H, Zabor EC, et al. Impact of smoking status at diagnosis on disease recurrence and death in upper tract urothelial carcinoma[J]. BJU Int.2012. doi: 10.1111/j.1464-410X.2012.11260.x
[11]Rink M. Xylinas E, Margulis V, et al. Impact of Smoking on Oncologic Outcomes of Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy[J]. Eur Urol,2012. doi:10.1016/j.eururo.2012.06.029.
[12]Raman JD, Ng CK, Scherr DS, et al. Impact of tumor location on prognosis for patients with upper tract urothelial carcinoma managed by radical nephroureterectomy [J]. Eur Urol,2010,57(6):1072-1079.
[13]Yafi FA, Novara G, Shariat SF, et al. Impact of tumour location versus multifocality in patients with upper tract urothelial carcinoma treated with nephroureterectomy and bladder cuff excision:a homogeneous series without perioperative chemotherapy[J]. BJU Int,2012,110(2 Pt 2):E7-13.
[14]Rink M, Ehdaie B, Cha EK, et al. Stage-Specific Impact of Tumor Location on Oncologic Outcomes in Patients With Upper and Lower Tract Urothelial Carcinoma Following Radical Surgery[J]. Eur Urol,2012,62(4):677-684.
[15]Cosentino M, Palou J, Gaya JM, et al. Upper urinary tract urothelial cell carcinoma: location as a predictive factor for concomitant bladder carcinoma[J]. World J Urol,2012. doi:10.1007/s00345-012-0877-2
[16]Zigeuner RE, Hutterer G, Chromecki T, et al. Bladder tumour development after urothelial carcinoma of the upper urinary tract is related to primary tumour location[J]. BJU Int, 2006,98(6):1181-1186.
[17]Raman JD, Shariat SF, Karakiewicz PI, et al. Does preoperative symptom classification impact prognosis in patients with clinically localized upper-tract urothelial carcinoma managed by radical nephroureterectomy?[J]. Urol Oncol,2011,29(6):716-723.
[18]Ito Y, Kikuchi E, Tanaka N, et al. Preoperative hydronephrosis grade independently predicts worse pathological outcomes in patients undergoing nephroureterectomy for upper tract urothelial carcinoma[J]. J Urol,2011,185(5):1621-1626.
[19]Ng CK, Shariat SF, Lucas SM, et al. Does the presence of hydronephrosis on preoperative axial CT imaging predict worse outcomes for patients undergoing nephroureterectomy for upper-tract urothelial carcinoma?[J]. Urol Oncol,2011,29(1):27-32.
[20]Messer JC, Terrell JD. Herman MP, et al. Multi-institutional validation of the ability of preoperative hydronephrosis to predict advanced pathologic tumor stage in upper-tract urothelial carcinoma[J]. Urol Oncol,2011. doi:10.1016/j.urolonc.2011.07.011
[21]Mullerad M, Russo P, Golijanin D, et al. Bladder cancer as a prognostic factor for upper tract transitional cell carcinoma[J]. J Urol,2004,172(6 Pt 1):2177-2181.
[22]Novara G, De Marco V. Gottardo F, et al. Independent predictors of cancer-specific survival in transitional cell carcinoma of the upper urinary tract:multi-institutional dataset from 3 European centers[J]. Cancer,2007,110(8):1715-1722.
[23]Boorjian S, Ng C, Munver R, et al. Impact of delay to nephroureterectomy for patients undergoing ureteroscopic biopsy and laser tumor ablation of upper tract transitional cell carcinoma[J]. Urology,2005,66(2):283-287.
[24]Waldert M. Karakiewicz PI, Raman JD, et al. A delay in radical nephroureterectomy can lead to upstaging[J]. BJU Int,2010,105(6):812-817.
[25]Gadzinski AJ, Roberts WW, Faerber GJ, et al. Long-term outcomes of immediate versus delayed nephroureterectomy for upper tract urothelial carcinoma[J]. J Endourol,2012, 26(5):566-573.
[26]Sundi D, Svatek RS, Margulis V, et al. Upper tract urothelial carcinoma:impact of time to surgery[J], Urol Oncol,2012,30(3):266-272.
[27]Stewart GD, Humphries K.J, Cutress ML, et al. Long-term comparative outcomes of open versus laparoscopic nephroureterectomy for upper urinary tract urothelial-cell carcinoma after a median follow-up of 13 years*[J]. J Endourol,2011,25(8):1329-1335.
[28]Ni S, Tao W. Chen Q, et al. Laparoscopic versus open nephroureterectomy for the treatment of upper urinary tract urothelial carcinoma:a systematic review and cumulative analysis of comparative studies[J]. EurUrol,2012,61(6):1142-1153.
[29]Xylinas E, Rink M, Cha EK, et al. Impact of Distal Ureter Management on Oncologic Outcomes Following Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma[J]. EurUrol,2012. http://dx.doi.org/10.1016/j.eururo.2012.04.052
[30]龚宇,杜传军,陈继民等.经尿道钬激光、电切及开放手术处理膀胱袖套-输尿管下段的对照研究[J].中华泌尿外科杂志,2012,33(5)：347-350.
[31]Miyake H, Hara 1, Gohji K, et al. The significance of lymphadenectomy in transitional cell carcinoma of the upper urinary tract[J]. Br J Urol,1998,82(4):494-498.
[32]Brausi MA, Gavioli M, De Luca G, et al. Retroperitoneal lymph node dissection (RPLD) in conjunction with nephroureterectomy in the treatment of infiltrative transitional cell carcinoma (TCC) of the upper urinary tract:impact on survival[J]. Eur Urol,2007,52(5): 1414-1418.
[33]Roscigno M, Cozzarini C, Bertini R, et al. Prognostic value of lymph node dissection in patients with muscle-invasive transitional cell carcinoma of the upper urinary tract[J]. Eur Urol,2008,53(4):794-802.
[34]Roscigno M, Shariat SF, Margulis V, et al. Impact of lymph node dissection on cancer specific survival in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy[J]. J Urol,2009,181(6):2482-2489.
[35]Rondo T, Hashimoto Y, Kobayashi H, et al. Template-based lymphadenectomy in urothelial carcinoma of the upper urinary tract:impact on patient survival[J]. Int J Urol, 2010,17(10):848-854.
[36]Lughezzani G, Jeldres C, Isbarn H, et al. A critical appraisal of the value of lymph node dissection at nephroureterectomy for upper tract urothelial carcinoma[J]. Urology,2010, 75(1):118-124.
[37]Mason RJ, Kassouf W, Bell DG, et al. The contemporary role of lymph node dissection during nephroureterectomy in the management of upper urinary tract urothelial carcinoma: the Canadian experience[J]. Urology,2012,79(4):840-845.
[38]陈明,徐丹枫,崔心刚等.上尿路移行细胞癌预后的多因素分析[J].第二军医大学学报,2008,(10)：1217-1220.
[39]Margulis V, Shariat SF, Matin SF, et al. Outcomes of radical nephroureterectomy:a series from the Upper Tract Urothelial Carcinoma Collaboration[J]. Cancer,2009,115(6): 1224-1233.
[40]Langner C, Hutterer G, Chromecki T, et al. pT classification, grade, and vascular invasion as prognostic indicators in urothelial carcinoma of the upper urinary tract[J]. Mod Pathol, 2006,19(2):272-279.
[41]Li WM, Li CC, Ke HL, et al. The prognostic predictors of primary ureteral transitional cell carcinoma after radical nephroureterectomy[J]. J Urol.2009,182(2):451-458; discussion 458.
[42]Li CC, Chang TH, Wu WJ, et al. Significant predictive factors for prognosis of primary upper urinary tract cancer after radical nephroureterectomy in Taiwanese patients[J]. Eur Urol,2008,54(5):1127-1134.
[43]Simone G, Papalia R, Loreto A, et al. Independent prognostic value of tumour diameter and tumour necrosis in upper urinary tract urothelial carcinoma[J]. BJU Int,2009,103(8): 1052-1057.
[44]Pieras E, Frontera G, Ruiz X, et al. Concomitant carcinoma in situ and tumour size are prognostic factors for bladder recurrence after nephroureterectomy for upper tract transitional cell carcinoma[J]. BJU Int,2010,106(9):1319-1323.
[45]Langner C, Hutterer G, Chromecki T, et al. Patterns of invasion and histological growth as prognostic indicators in urothelial carcinoma of the upper urinary tract[J]. Virchows Arch, 2006,448(5):604-611.
[46]Remzi M, Haitel A, Margulis V, et al. Tumour architecture is an independent predictor of outcomes after nephroureterectomy:a multi-institutional analysis of 1363 patients[J]. BJU Int,2009,103(3):307-311.
[47]Fritsche HM, Novara G, Burger M, et al. Macroscopic sessile tumor architecture is a pathologic feature of biologically aggressive upper tract urothelial carcinoma[J]. Urol Oncol,2012,30(5):666-672.
[48]Wheat JC, Weizer AZ, Wolf JS, Jr., et al. Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ confined urothelial carcinoma following radical nephroureterectomy[J]. Urol Oncol,2012,30(3):252-258.
[49]Langner C, Hutterer G, Chromecki T, et al. Tumor necrosis as prognostic indicator in transitional cell carcinoma of the upper urinary tract[J]. J Urol,2006,176(3):910-913; discussion 913-914.
[50]Lee SE, Hong SK, Han BK, et al. Prognostic significance of tumor necrosis in primary transitional cell carcinoma of upper urinary tract[J]. Jpn J Clin Oncol,2007,37(1):49-55.
[51]Zigeuner R, Shariat SF, Margulis V, et al. Tumour necrosis is an indicator of aggressive biology in patients with urothelial carcinoma of the upper urinary tract[J]. Eur Urol,2010, 57(4):575-581.
[52]Seitz C, Gupta A. Shariat SF, et al. Association of tumor necrosis with pathological features and clinical outcome in 754 patients undergoing radical nephroureterectomy for upper tract urothelial carcinoma:an international validation study[J]. J Urol,2010,184(5): 1895-1900.
[53]Chromecki TF. Cha EK, Fajkovic H. et al. The impact of tumor multifocality on outcomes in patients treated with radical nephroureterectomy[J]. Eur Urol,2012.61(2):245-253.
[54]Bolenz C, Fernandez MI, Trojan L, et al. Lymphovascular invasion and pathologic tumor stage are significant outcome predictors for patients with upper tract urothelial carcinoma[J]. Urology,2008,72(2):364-369.
[55]Lin WC, Hu FC, Chung SD, et al. The role of lymphovascular invasion in predicting the prognosis of clinically localized upper tract urothelial carcinoma (pT1-3cN0MO)[J]. J Urol,2008,180(3):879-884:discussion 884-875.
[56]Kikuchi E, Margulis V, Karakiewicz PI, et al. Lymphovascular invasion predicts clinical outcomes in patients with node-negative upper tract urothelial carcinoma[J]. J Clin Oncol, 2009,27(4):612-618.
[57]Novara G, Matsumoto K, Kassouf W, et al. Prognostic role of lymphovascular invasion in patients with urothelial carcinoma of the upper urinary tract:an international validation study[J]. Eur Urol,2010,57(6):1064-1071.
[58]Colin P, Ouzzane A, Yates DR, et al. Influence of positive surgical margin status after radical nephroureterectomy on upper urinary tract urothelial carcinoma survival[J]. Ann Surg Oncol,2012,19(11):3613-3620.
[59]吉日嘎拉,王璠,余大海,et a1.凋亡抑制蛋白Livin在上尿路移行细胞癌中的表达及其与预后的关系[J].中国实验诊断学,2012,(10)：1845-1848.
[60]费翔,宋永胜.脂肪酸合成酶在上尿路移行细胞癌组织表达的临床意义及预后相关性分析[J].山西医药杂志,2012,(01)：20-22.
[61]Lughezzani G, Burger M, Margulis V, et al. Prognostic factors in upper urinary tract urothelial carcinomas:a comprehensive review of the current literature[J]. Eur Urol,2012, 62(1):100-114.
[1]Laing R, Waning B, Gray A, Ford N, t Hoen E.25 years of the WHO essential medicines lists:progress and challenges [J]. Lancet 2003;361(9370):1723-9.
[2]The selection and use of essential medicines. Report of the WHO Expert Committee,2002 (including the 12th Model list of essential medicines) [J]. World Health Organ Tech Rep Ser 2003;914:i-vi.1-126.
[3]徐文娟.我国基本药物目录及其实施现况[D].：复旦大学,2012.
[4]关于印发《关于建立国家基本药物制度的实施意见》的通知,卫药政发[2009]78号,2009.
[5]关于印发《国家基本药物目录管理办法(暂行)》的通知.卫药政发[2009]79号,2009.
[6]中华人民共和国卫生部.《国家基本药物目录(基层医疗卫生机构配备使用部分)》(2009版)(卫生部令第69号).2009.
[7]关于在试点地区加快实施国家基本药物制度的通知,甘卫规财发[2010]180号Available from:UR L:http://www.gsws.gov.cn/html/2/5/14828.htm
[8]郑访江.医疗卫生管理.国家基本药物制度[Z].甘肃年鉴：2011.
[9]甘肃省卫生厅,《甘肃省国家基本药物增补目录》(2011年版·基层部分),2011.
[10]蒋虹丽,陈鸣声,陈文,张璐莹,茅雯辉.国家基本药物制度实施的阶段性效果和问题分析[J].中国卫生信息管理杂志,2012,9(1)：40-43.
[11]孙强,左根永,李凯,孟庆跃,何平.实施基本药物制度是否降低了农村居民的医药费用负担：来自安徽三县区的经验[J].中国卫生经济,2012,31(4)：65-67.
[12]沈建通,杨晓妍,李幼平等.甘肃省临洮县新添中心卫生院基本情况现况调查[J].中国循证医学杂志,2011,11(2)：125-130.
[13]李鸿浩,杨晓妍,李幼平,等.甘肃省临洮县新添中心卫生院2008-2010年度住院疾病构成与费用情况调查[J].中国循证医学杂志,2011,11(2)：131-7.
[14]盛来运,严建辉总编.一、主题报告篇,2011年社会事业发展报告[z].中国发展报告：2012,.
[15]关于印发《甘肃省国家基本药物管理办法(试行)》的通知Available from:URL: http://www.gsws.gov.cn/html/2/9/13967.htm.
[16]王莉,周帮旻,宋佳佳等.25国基本药物目录循证评价[J].中国循证医学杂志,2009,9(7)：754-764.
[17]耿劲松,董建成,蒋葵等.我国基层医疗卫生机构增补药物目录的循证分析[J].中国循证医学杂志,2011,11(1)：35-38.
[18]尹爱田,李新泰.山东省基本药物制度对乡镇卫生院门诊服务的影响研究[J].中国卫生经济,2011,30(4)：20-22.
[19]张丽青,黄术生.基本药物制度实施对乡镇卫生院的影响和建议[J].中国卫生事业竹理,2011,28(6)：438-439.
[20]何平,刘博,孙强等.基本药物制度改革前后乡镇卫生院药品价格比较——基于安徽省三县的抽样调查[J].中国卫生政策研究,2011,04(7)：11-16.
[21]于风华,孟庆跃,王健等.基本药物零差率销售对乡镇卫生院经济补偿的影响研究[J].中国卫生经济,2011,30(1)：42-44.
[22]贾金忠,谢一萍,段琳等.基本药物制度实施与乡镇卫生院补偿机制转变[J].中国医院管理,2011,31(10)：37-39.
[23]李新泰,工文华,尹爱田等.山东省基本药物制度对乡镇卫生院合理用药的影响[J].中国卫生经济,2011,30(4)：22-23.
[24]孟锐,邹萍,张师瑞等.完善基本药物制度促进临床合理用药[J].中国药业,2010,19(4)：1-2.
[25]王晓蓉,皮墨.基层医疗卫生机构实施基本药物制度的补偿机制探讨[J].中国卫生经济,2011,30(9)：27-28.
[1]沈建通,杨晓妍,李幼平等.甘肃省临洮县新添中心卫生院基本情况现况调查[J].中国循证医学杂志,2011,11(2)：125-130.
[2]中华人民共和国住房和城乡建设部,中华人民共和国国家发展和改革委员会,乡镇卫生院建设标准[S],北京：中国计划出版社,2009.
[3]汤光,李大魁,袁锁中主编,《优良药房工作规范》(2005年版)(一)[J].中国医院药房药学杂志,2006.26(5)：503507.
[4]刘彦,基层药房的建设和管理[J].管理观察,2010,32：208-209
[5]卫生部、国家中医药管理局和总后勤部卫生部,医疗机构药事管理规定[S],卫医政发[2011],11号
[6]国务院办公厅.建立和规范政府办基层医疗卫生机构基本药物采购机制的指导意见[S],国办发[2010]56号
[7]中华人民共和国国务院令第360号.中华人民共和国药品管理法实施条例[S].2002年9月15口.
[8]主席令第45号.中华人民共和国药品管理法[S].2001年12月1日.
[9]中华人民共和国卫生部令81号、中华人民共和国卫生部,《药品不良反应报告和监测管理办法》[S].